10x Genomics (TXG) 10-Q 12 Nov 19 2019 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2019	Oct. 31, 2019
Entity Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Registrant Name	10x Genomics, Inc.
Entity Central Index Key	0001770787
Entity Address, State or Province	CA
Entity Incorporation, State or Country Code	DE
Title of 12(b) Security	Class A common stock
Trading Symbol	TXG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Common Class A [Member]
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		20,900,524
Common Class B [Member]
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		75,269,430

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 427,436	$ 65,080
Accounts receivable, net	26,150	28,088
Inventory	13,305	8,570
Prepaid expenses and other current assets	7,253	4,498
Total current assets	474,144	106,236
Property and equipment, net	46,840	11,127
Restricted cash	50,053	5,008
Other assets	1,778	1,939
Total assets	572,815	124,310
Current liabilities:
Accounts payable	11,959	8,792
Accrued compensation and related benefits	7,850	7,047
Accrued expenses and other current liabilities	14,267	8,172
Term loans, current portion	7,383	4,187
Accrued legal expenses	3,695	1,769
Deferred revenue, current	3,082	2,395
Total current liabilities	48,236	32,362
Term loans, noncurrent portion	22,307	25,489
Accrued contingent liabilities	62,501	38,000
Deferred revenue, noncurrent	1,202	1,102
Deferred rent, noncurrent	16,170	3,329
Other noncurrent liabilities	951	771
Total liabilities	151,367	101,053
Commitments and contingencies (Note 6)
Convertible preferred stock, $0.00001 par value, no shares authorized and no shares issued and outstanding as of September 30, 2019; 67,904,871 shares authorized and 67,704,278 shares issued and outstanding as of December 31, 2018; aggregate liquidation preference of $242,588 as of December 31, 2018		243,244
Stockholders' equity (deficit):
Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued and outstanding as of September 30, 2019 and December 31, 2018
Common stock, $0.00001 par value; 1,100,000,000 shares authorized as of September 30, 2019, 96,118,804 shares issued and outstanding as of September 30, 2019; 190,955,000 shares authorized as of December 31, 2018, 14,549,801 shares issued and outstanding as of December 31, 2018	2	1
Additional paid-in capital	676,839	11,165
Accumulated deficit	(255,233)	(231,116)
Accumulated other comprehensive loss	(160)	(37)
Total stockholders' equity (deficit)	421,448	(219,987)
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	$ 572,815	$ 124,310

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Convertible Preferred Stock, Par Value	$ 0.00001	$ 0.00001
Convertible Preferred Stock, Shares Authorized	0	67,904,871
Convertible Preferred Stock, Shares Issued	0	67,704,278
Convertible Preferred Stock, Shares Outstanding	0	67,704,278
Convertible Preferred Stock, Liquidation Preference		$ 242,588
Preferred Stock, Par Value	$ 0.00001	$ 0.00001
Preferred Stock, Shares Authorized	100,000,000	0
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value	$ 0.00001	$ 0.00001
Common Stock, Shares Authorized	1,100,000,000	190,955,000
Common Stock, Shares Issued	96,118,804	14,549,801
Common Stock, Outstanding	96,118,804	14,549,801

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue	$ 61,207	$ 36,607	$ 170,604	$ 95,759
Cost of revenue	15,480	5,241	44,451	13,761
Gross profit	45,727	31,366	126,153	81,998
Operating expenses:
Research and development	22,209	11,085	55,208	34,457
In-process research and development		16,104		22,310
Selling, general and administrative	32,614	19,110	92,078	61,030
Accrued contingent liabilities			1,360
Total operating expenses	54,823	46,299	148,646	117,797
Loss from operations	(9,096)	(14,933)	(22,493)	(35,799)
Other income (expense):
Interest income	481	294	986	755
Interest expense	(708)	(659)	(2,087)	(1,721)
Other expenses, net	(272)	(31)	(413)	(151)
Total other expense	(499)	(396)	(1,514)	(1,117)
Loss before provision for income taxes	(9,595)	(15,329)	(24,007)	(36,916)
Provision for income taxes	8	16	110	45
Net loss	(9,603)	(15,345)	(24,117)	(36,961)
Other comprehensive income (loss):
Foreign currency translation adjustment	(126)	1	(123)	17
Comprehensive loss	$ (9,729)	$ (15,344)	$ (24,240)	$ (36,944)
Net loss per share attributable to common stockholders, basic and diluted	$ (0.33)	$ (1.13)	$ (1.21)	$ (2.80)
Weighted-average shares of common stock used in computing net loss per share attributable to common stockholders, basic and diluted	29,184,218	13,587,288	19,904,184	13,188,322

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Common stock [Member]	Additional paid-in capital [Member]	Accumulated deficit	Accumulated other comprehensive income (loss)	Common class A [Member]	Common class A [Member]Common stock [Member]	Common class A [Member]Additional paid-in capital [Member]	Common class B [Member]	Common class B [Member]Common stock [Member]	Common class B [Member]Additional paid-in capital [Member]	Convertible preferred stock [Member]	Series D convertible preferred stock [Member]
Beginning balance at Dec. 31, 2017	$ (112,509)	$ 1	$ 6,136	$ (118,631)	$ (15)
Beginning balance, shares at Dec. 31, 2017		12,883,930
Beginning balance of temporary equity at Dec. 31, 2017												$ 158,414
Beginning balance of temporary equity, shares at Dec. 31, 2017												59,730,213
Issuance of Class A common stock upon exercise of stock options, shares							463,400
Issuance of Class A common stock upon exercise of stock options						$ 313		$ 313
Issuance of warrants to purchase common stock	150		150
Vesting of shares subject to repurchase, including early exercised options	9		9
Stock-based compensation	488		488
Net loss	(15,693)			(15,693)
Other comprehensive income (loss)	(11)				(11)
Ending balance of temporary equity at Mar. 31, 2018												$ 158,414
Ending balance of temporary equity, shares at Mar. 31, 2018												59,730,213
Ending balance at Mar. 31, 2018	(127,253)	$ 1	7,096	(134,324)	(26)
Ending balance, shares at Mar. 31, 2018		13,347,330
Beginning balance at Dec. 31, 2017	(112,509)	$ 1	6,136	(118,631)	(15)
Beginning balance, shares at Dec. 31, 2017		12,883,930
Beginning balance of temporary equity at Dec. 31, 2017												$ 158,414
Beginning balance of temporary equity, shares at Dec. 31, 2017												59,730,213
Net loss	(36,961)
Ending balance of temporary equity at Sep. 30, 2018												$ 208,292
Ending balance of temporary equity, shares at Sep. 30, 2018												64,954,871
Ending balance at Sep. 30, 2018	(146,772)	$ 1	8,817	(155,592)	2
Ending balance, shares at Sep. 30, 2018		13,942,336
Beginning balance at Mar. 31, 2018	(127,253)	$ 1	7,096	(134,324)	(26)
Beginning balance, shares at Mar. 31, 2018		13,347,330
Beginning balance of temporary equity at Mar. 31, 2018												$ 158,414
Beginning balance of temporary equity, shares at Mar. 31, 2018												59,730,213
Issuance of Series D convertible preferred stock, net of issuance cost, shares													5,224,658
Issuance of Series D convertible preferred stock, net of issuance cost													$ 49,878
Issuance of Class A common stock upon exercise of stock options, shares							184,775
Issuance of Class A common stock upon exercise of stock options						148		148
Vesting of shares subject to repurchase, including early exercised options	9		9
Stock-based compensation	518		518
Net loss	(5,923)			(5,923)
Other comprehensive income (loss)	27				27
Ending balance of temporary equity at Jun. 30, 2018												$ 208,292
Ending balance of temporary equity, shares at Jun. 30, 2018												64,954,871
Ending balance at Jun. 30, 2018	(132,474)	$ 1	7,771	(140,247)	1
Ending balance, shares at Jun. 30, 2018		13,532,105
Issuance of Class A common stock upon exercise of stock options, shares							410,231
Issuance of Class A common stock upon exercise of stock options						291		291
Vesting of shares subject to repurchase, including early exercised options	166		166
Stock-based compensation	589		589
Net loss	(15,345)			(15,345)
Other comprehensive income (loss)	1				1
Ending balance of temporary equity at Sep. 30, 2018												$ 208,292
Ending balance of temporary equity, shares at Sep. 30, 2018												64,954,871
Ending balance at Sep. 30, 2018	(146,772)	$ 1	8,817	(155,592)	2
Ending balance, shares at Sep. 30, 2018		13,942,336
Beginning balance at Dec. 31, 2018	(219,987)	$ 1	11,165	(231,116)	(37)
Beginning balance, shares at Dec. 31, 2018		14,549,801
Beginning balance of temporary equity at Dec. 31, 2018	$ 243,244											$ 243,244
Beginning balance of temporary equity, shares at Dec. 31, 2018	67,704,278											67,704,278
Issuance of Class A common stock upon exercise of stock options, shares							898,858
Issuance of Class A common stock upon exercise of stock options						923		923
Vesting of shares subject to repurchase, including early exercised options	$ 72		72
Stock-based compensation	1,359		1,359
Net loss	(3,636)			(3,636)
Other comprehensive income (loss)	(24)				(24)
Ending balance of temporary equity at Mar. 31, 2019												$ 243,244
Ending balance of temporary equity, shares at Mar. 31, 2019												67,704,278
Ending balance at Mar. 31, 2019	(221,293)	$ 1	13,519	(234,752)	(61)
Ending balance, shares at Mar. 31, 2019		15,448,659
Beginning balance at Dec. 31, 2018	(219,987)	$ 1	11,165	(231,116)	(37)
Beginning balance, shares at Dec. 31, 2018		14,549,801
Beginning balance of temporary equity at Dec. 31, 2018	$ 243,244											$ 243,244
Beginning balance of temporary equity, shares at Dec. 31, 2018	67,704,278											67,704,278
Net loss	$ (24,117)
Ending balance of temporary equity at Sep. 30, 2019												$ 0
Ending balance of temporary equity, shares at Sep. 30, 2019	0											0
Ending balance at Sep. 30, 2019	$ 421,448	$ 2	676,839	(255,233)	(160)
Ending balance, shares at Sep. 30, 2019		96,118,804
Beginning balance at Mar. 31, 2019	(221,293)	$ 1	13,519	(234,752)	(61)
Beginning balance, shares at Mar. 31, 2019		15,448,659
Beginning balance of temporary equity at Mar. 31, 2019												$ 243,244
Beginning balance of temporary equity, shares at Mar. 31, 2019												67,704,278
Issuance of Class A common stock upon exercise of stock options, shares							696,723
Issuance of Class A common stock upon exercise of stock options						1,082		1,082
Vesting of shares subject to repurchase, including early exercised options	89		89
Stock-based compensation	3,025		3,025
Net loss	(10,878)			(10,878)
Other comprehensive income (loss)	27				27
Ending balance of temporary equity at Jun. 30, 2019												$ 243,244
Ending balance of temporary equity, shares at Jun. 30, 2019												67,704,278
Ending balance at Jun. 30, 2019	(227,948)	$ 1	17,715	(245,630)	(34)
Ending balance, shares at Jun. 30, 2019		16,145,382
Issuance of Class A common stock upon exercise of stock options, shares							508,120
Issuance of Class A common stock upon exercise of stock options						1,013		1,013
Conversion of convertible preferred stock into Class B common stock, shares										67,704,278
Conversion of convertible preferred stock into Class B common stock									$ 243,244	$ 1	$ 243,243
Conversion of convertible preferred stock into Class B common stock, shares												(67,704,278)
Conversion of convertible preferred stock into Class B common stock												$ (243,244)
Issuance of Class A common stock upon initial public offering, net of issuance costs, shares							11,500,000
Issuance of Class A common stock upon initial public offering, net of issuance costs						$ 410,824		$ 410,824
Cashless exercise of Class A common stock warrants, shares							261,024
Vesting of shares subject to repurchase, including early exercised options	170		170
Stock-based compensation	3,874		3,874
Net loss	(9,603)			(9,603)
Other comprehensive income (loss)	$ (126)				(126)
Ending balance of temporary equity at Sep. 30, 2019												$ 0
Ending balance of temporary equity, shares at Sep. 30, 2019	0											0
Ending balance at Sep. 30, 2019	$ 421,448	$ 2	$ 676,839	$ (255,233)	$ (160)
Ending balance, shares at Sep. 30, 2019		96,118,804

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Operating activities:
Net loss	$ (24,117)	$ (36,961)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	4,221	3,015
Stock-based compensation	8,258	1,595
Loss on disposal of property and equipment	614	195
Accretion of discount on term loan	72	326
Changes in operating assets and liabilities:
Accounts receivable	1,938	(5,756)
Inventory	(4,735)	(2,011)
Prepaid expenses and other current assets	(2,756)	(1,030)
Other assets	49	(835)
Accounts payable	2,686	(1,825)
Accrued compensation and other related benefits	838	(199)
Deferred revenue	787	1,300
Accrued contingent liabilities	24,501
Accrued expenses and other current liabilities	2,550	16,211
Deferred rent, noncurrent	12,841	470
Other noncurrent liabilities	180	95
Net cash provided by (used in) operating activities	27,927	(25,410)
Investing activities:
Purchases of property and equipment	(36,186)	(3,880)
Net cash used in investing activities	(36,186)	(3,880)
Financing activities:
Proceeds from term loans		19,512
Payments on term loans		(704)
Proceeds from borrowings under revolver	11,000
Payments on borrowings under revolver	(11,000)
Payments on capital lease obligations		(69)
Proceeds from issuance of common stock upon initial public offering, net of issuance costs	412,679
Proceeds from issuance of preferred stock, net of issuance costs		49,878
Proceeds from issuance of common stock upon exercise of stock options	3,018	872
Net cash provided by financing activities	415,697	69,489
Effect of exchange rates on changes in cash, cash equivalents, and restricted cash	(37)	9
Net increase in cash, cash equivalents, and restricted cash	407,401	40,208
Cash, cash equivalents, and restricted cash at beginning of period	70,088	47,857
Cash, cash equivalents, and restricted cash at end of period	477,489	88,065
Supplemental disclosures of cash flow information:
Cash paid for interest	1,722	1,455
Cash paid for taxes	22
Noncash investing and financing activities
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities	6,511	$ 594
Conversion of convertible preferred stock into common stock upon initial public offering	243,244
Deferred offering costs in accounts payable and accrued expenses and other current liabilities	$ 1,855

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation Organization and Description of Business 10x Genomics, Inc. (the “Company”) was incorporated in the state of Delaware on July 2, 2012. The Company’s integrated solutions include the Company’s Chromium instruments, which are referred to as “instruments”, its enzymes, reagents, microfluidic chips and other consumable products, which are referred to as “consumables”, and software for analyzing biological systems. These solutions guide customers through the workflow from sample preparation to next-generation sequencing to subsequent analysis and visualization. Each of the Company’s solutions is designed to interrogate a major class of biological information that is impactful to researchers. The Company began commercial and manufacturing operations and selling its instruments and consumables in 2015. The Company’s headquarters is located in Pleasanton, California and has wholly-owned subsidiaries in Sweden, Netherlands, Singapore, Germany and China. Initial Public Offering The Company’s registration statement on Form S-1 Immediately prior to the completion of the IPO, 67,704,278 shares of convertible preferred stock then outstanding converted into an equivalent number of shares of Class B common stock, 8,050,000 shares of Historical Class A common stock converted into an equivalent number of shares of Class B common stock, and 8,095,382 shares of Historical Class B common stock converted into an equivalent number of shares of Class A common stock. The Company has reflected the renaming of Historical Class A common stock and Historical Class B common stock to Class B common stock and Class A common stock, respectively, throughout the document and all instances of Class A common stock and Class B common stock reflect this change. Immediately prior to the completion of the IPO, the Company filed its Amended and Restated Certificate of Incorporation, which authorizes a total of 1,000,000,000 shares of Class A common stock, 100,000,000 shares of Class B common stock and 100,000,000 shares of preferred stock. During the third quarter of 2019, 484,484 shares of Class B common stock were converted to Class A common stock. As of September 30, 2019, Class A common stock and Class B common stock issued and outstanding was 20,849,374 and 75,269,430, respectively. Each share of Class A common stock is entitled to one vote per share. Each share of Class B common stock is entitled to ten votes per share and is convertible at any time into one share of Class A common stock. Basis of Presentation The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The condensed consolidated balance sheets at December 31, 2018 have been derived from the audited consolidated financial statements of the Company at that date. Certain information and footnote disclosures typically included in the Company’s audited consolidated financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the Company’s financial position, results of operations, comprehensive loss and cash flows for the periods presented, but are not necessarily indicative of the results of operations to be anticipated for any future annual or interim period. All intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2018 included in the final prospectus for the IPO filed with the SEC on September 12, 2019. Liquidity While the Company has generated positive cash flows from operations of $27.9 million for the nine months ended September 30, 2019, the Company has incurred significant losses and has historically had negative cash flows from operations. As of September 30, 2019, the Company had cash and cash equivalents of $427.4 million and an accumulated deficit of $255.2 million. Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth. The Company believes that its cash and cash equivalents balance as of September 30, 2019, which includes the proceeds from the IPO, and borrowing capacity under existing credit agreements provide sufficient capital resources to continue its operations for at least 12 months from the issuance date of the accompanying condensed consolidated financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expense. These judgments, estimates and assumptions are used for, but not limited to, revenue recognition, inventory valuation and write-downs, loss contingencies, accounting for assets acquisitions and the fair value of common stock and stock option awards. The Company bases its estimates on various factors and information, which may include, but are not limited to, history and prior experience, the Company’s forecasts and future plans, current economic conditions and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. Actual results may differ from those estimates, and the differences may be material. Segment Information The Company operates as a single operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance. Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and are stated at fair value. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows (in thousands): September 30, December 31, Cash and cash equivalents $ 427,436 $ 65,080 Restricted cash 50,053 5,008 Total cash, cash equivalents and restricted cash $ 477,489 $ 70,088 Fair Value of Financial Instruments The Company determines the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows: Level 1: Quoted prices in active markets for identical instruments Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Money market funds are highly liquid investments and are actively traded. The pricing information for the Company’s money market funds are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy. There were no transfers between Levels 1, 2 or 3 for any of the periods presented. As of September 30, 2019 and December 31, 2018, the Company held $406.9 million and $44.5 million in money market funds, respectively, with no unrealized gains or losses. The Company has issued common stock warrants for which fair value is determined using Level 3 inputs. See Note 5 for more on the common stock warrants. Accounts Receivable, Net Accounts receivable consist of amounts due from customers for the sales of products and services. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability is no longer reasonably assured based on historical experience and specific customer collection issues. The allowance for doubtful accounts was $0.1 million and $0.3 million as of September 30, 2019 and December 31, 2018, respectively. Business Concentrations The Company’s instruments are mostly assembled and tested by a single contract manufacturer in the United States. The Company’s agreement with the contract manufacturer expires in 2020 and may be terminated by either party for any reason by providing the other party with at least 30 days written notice. The Company’s agreement with the contract manufacturer contains purchase commitments. In addition, the Company is reliant on several suppliers for key components for its reagent kits. A significant disruption in the operations of the contract manufacturer or suppliers may impact the production of the Company’s products for a substantial period of time, which could have a material adverse effect on its business, financial condition and results of operations. Concentrations Financial instruments that potentially subject the Company to credit risk consist of cash equivalents and accounts receivable. The Company’s cash and cash equivalents are primarily held with a large financial institution in the United States and deposits exceed the Federal Deposit Insurance Corporation’s insurance limit. The Company’s debt is with this same financial institution. The Company performs periodic evaluations of the risks associated with its investments and the relative credit standing of this financial institution. The Company performs ongoing credit evaluations of its customers’ financial condition. The Company does not require collateral from its customers but may require upfront payments from certain customers. The Company has not experienced significant credit losses to date. For the three and nine months ended September 30, 2018 and 2019, no single customer represented more than 10% of revenue. As of September 30, 2019 and December 31, 2018, no single customer represented more than 10% of the Company’s outstanding accounts receivable. Substantially all the Company’s long-lived assets are located in the United States. Inventory Inventory is recorded at the lower of cost, determined on a first-in, first-out basis, Property and Equipment, Net Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of the assets. Assets held under capital leases are recorded at the lower of the net present value of the minimum lease payments or the fair value of the leased assets at the inception of the lease. Amortization expense is computed using the straight-line method over the shorter of the estimated useful lives of the leased assets or the period of the related lease. Amortization of assets under capital leases is included in depreciation expense. Impairment of Long-Lived Assets The Company evaluates long-lived assets, such as property and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist and the undiscounted future cash flows that the assets are expected to generate are less than the carrying value of the assets, the Company reduces the carrying amount of the assets to their estimated fair values based on a discounted cash flow approach or, when available and appropriate, to comparable market values. There were no impairment losses recorded for the three and nine month periods ended September 30, 2019 and 2018. Product Warranties The Company generally provides a one-year warranty Deferred Revenue Deferred revenue consists of payments received in advance of revenue recognition primarily related to instrument service agreements, also referred to as extended warranties. Revenue under these agreements is recognized over the related service period. Deferred revenue that will be recognized during the 12 months following the balance sheet date is recorded as current portion of deferred revenue and the remaining portion is recorded as long term. Accrued Contingent Liabilities Accrued contingent liabilities represents the Company’s estimates of possible losses on pending litigations, including related accrued royalties that are both probable and reasonably estimable. See Note 6. Revenue Recognition Commencing on January 1, 2019, the Company recognized revenues in accordance with Accounting Standards Codification ( “ ASC ” ) Topic 606 – Revenue from Contracts with Customers. The Company generates revenue from sales of products and services. The Company’s products consist of instruments and consumables. The Company also sells instrument service agreements which relate to extended warranties. The Company recognizes revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. In instances where right of payment or transfer of title is contingent upon the customer’s acceptance of the product, revenue is deferred until all acceptance criteria have been met. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year one-year The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts. Contract Costs Sales commissions earned by the Company’s sales force are considered incremental and recoverable costs of obtaining a contract with a customer. Sale commissions related to the sale of extended warranties are deferred and amortized on a straight-line basis over the service term, which is typically greater than 1 year from the contract date. Amortization of deferred commissions is included in sales and marketing expenses in the accompanying condensed consolidated statements of operations and comprehensive loss. Cost of Revenue Costs of revenue primarily consist of manufacturing costs incurred in the production process, including personnel and related costs, component materials, labor and overhead, packaging and delivery costs and allocated costs including facilities and information technology. In addition, costs of product revenue includes royalty costs for licensed technologies included in the Company’s products, warranty costs and provisions for slow-moving and obsolete inventory. In addition, cost of revenue includes estimated accrued royalties related to the Bio-Rad Shipping and Handling Costs Shipping and handling charged to customers are recorded as revenue. Shipping and handling costs are included in the Company’s cost of revenue. Research and Development Research and development costs are expensed in the period incurred. Research and development expense consists of personnel and related costs, independent contractor costs, laboratory supplies, equipment maintenance, prototype and materials expenses, amortization of developed technology and intangibles and allocated costs including facilities and information technology. See Note 3 for discussion of in-process research Stock-Based Compensation The Company estimates the fair value of share-based payment awards granted to employees and directors on the grant date using the Black-Scholes option-pricing model. The fair value of share-based payment awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. Share-based payment awards that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based awards. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and the expected stock price volatility over the expected term. For all stock options granted, the Company calculated the expected term using the simplified method for “plain vanilla” stock option awards. The Company has limited publicly available stock information and therefore, the Company has used the historical volatility of the stock price of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues Stock-based compensation expense for nonemployee stock options is measured based on fair market value using the Black-Scholes option pricing model and is recorded as the options vest. Prior to January 1, 2019, nonemployee stock options subject to vesting were revalued periodically over the requisite service period, which was generally the same as the vesting term of the award. From January 1, 2019, the grant date fair market value of nonemployee stock options is recognized in the consolidated statements of operations on a straight-line basis over the requisite service period and forfeitures are recognized as they occur. Foreign Currency For foreign subsidiaries where the functional currency is the local currency, assets and liabilities are translated to the U.S. dollar using month-end exchange For foreign subsidiaries where the functional currency is the U.S. dollar, monetary assets and liabilities are remeasured using exchange rates in effect at the balance sheet dates and non-monetary assets Income Taxes The Company uses the asset and liability method of accounting for income taxes, in which deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be reversed. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that includes the enactment date. A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company’s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not (greater than 50% likely) to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision. The Company calculates the current and deferred income tax provision based on estimates and assumptions that could differ from the actual results reflected in income tax returns filed in subsequent years. Adjustments based on filed income tax returns are recorded when identified. The amount of income tax paid is subject to examination by U.S. federal and state tax authorities. The estimate of the potential outcome of any uncertain tax issue is subject to management’s assessment of the relevant risks, facts and circumstances existing at that time. To the extent the assessment of such tax position changes, the change in estimate is recorded in the period in which the determination is made. Net Loss Per Share Net loss per share of common stock is computed using the two-class method The Company’s participating securities included the Company’s convertible preferred stock, as the holders are entitled to receive noncumulative dividends on a pari passu basis in the event that a dividend is paid on common stock. The Company also considers any shares issued on the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. For the calculation of diluted net loss per share, basic net loss per share attributable to common stockholders is adjusted by the effect of dilutive securities, including convertible preferred stock, awards under the Company’s equity compensation plan and common stock warrants. Diluted net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. Acquisitions of Assets The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the requirements of a business. The Company accounts for an asset acquisition under Accounting Standards Codification (“ASC”), Business Combinations Topic 805, Subtopic 50 the non-monetary identifiable In-process Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. Recently Adopted Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting Compensation—Stock Compensation Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) right-of-use In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other – Internal Use Software (Subtopic 350-40) internal-use 350-40,

Acquisition

Acquisition	9 Months Ended
	Sep. 30, 2019
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Acquisition	3. Acquisition In March 2018, the Company acquired all of the outstanding shares of Epinomics, Inc. for $22.2 million inclusive of acquisition costs of $0.3 million. Of this amount, $6.2 million was due upon close of the acquisition and $16.0 million was due upon the amendment and assignment of a license agreement with the Board of Trustees of the Leland Stanford Junior University which occurred in August 2018. The technology licenses acquired in this transaction will enable the Company to develop products for epigenetics research. The transaction was accounted for as an asset acquisition. As the technology licenses acquired did not have alternative future use, the Company recognized charges of $16.0 million and $22.2 million during the three and nine months ended September 30, 2018, respectively, related to this transaction which are included as a component of in-process

Other Financial Statement Infor

Other Financial Statement Information	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Financial Statement Information	4. Other Financial Statement Information Inventory Inventory was comprised of the following as of the dates indicated (in thousands): September 30, December 31, Purchased materials $ 4,365 $ 3,052 Work in progress 4,525 2,553 Finished goods 4,415 2,965 Inventory $ 13,305 $ 8,570 Accrued Compensation and Related Benefits Accrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands): September 30, December 31, Accrued bonus $ 4,517 $ 3,545 Accrued commissions 1,757 2,299 Other 1,576 1,203 Accrued compensation and related benefits $ 7,850 $ 7,047 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands): September 30, December 31, Accrued royalties for licensed technologies $ 1,814 $ 1,571 Accrued property and equipment 5,367 990 Accrued consulting 763 741 Product warranties 409 804 Customer deposits 792 381 Taxes payable 740 738 Other 4,382 2,947 Accrued expenses and other current liabilities $ 14,267 $ 8,172 Product Warranties Changes in the reserve for product warranties were as follows for the periods indicated (in thousands): September 30, December 31, Beginning of period $ 804 $ 174 Additions charged to cost of revenue 408 1,685 Repairs and replacements (803 ) (1,055 ) End of period $ 409 $ 804 Revenue and Deferred Revenue As of September 30, 2019, the aggregate amount of the transaction price allocated to remaining performance obligations was $4.3 million, of which approximately 72% is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. These contract liabilities of $4.3 million consisted of deferred revenue related to extended warranty service agreements, and as of September 30, 2019, the short-term portion was $3.1 million. Revenue recorded during the three months and nine months ended September 30, 2019 included $0.6 million and $1.9 million, respectively, of previously deferred revenue that was included in contract liabilities as of the adoption date of January 1, 2019. Contract assets as of the adoption date of January 1, 2019 and September 30, 2019 were not material. The following table represents revenue by source for the periods indicated (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Instruments $ 10,377 $ 9,193 $ 25,527 $ 25,057 Consumables 49,745 26,810 142,134 69,292 Services 1,085 604 2,943 1,410 Total revenue $ 61,207 $ 36,607 $ 170,604 $ 95,759 The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 North America $ 35,838 $ 21,391 $ 97,293 $ 56,932 Europe, Middle East and Africa 12,136 8,228 36,634 21,953 China 7,046 4,248 22,453 9,710 Asia Pacific 6,187 2,740 14,224 7,164 Total revenue $ 61,207 $ 36,607 $ 170,604 $ 95,759 Revenue for the United States, which is included in North America in the table above, was 57% and 56% of consolidated revenue for the three months ended September 30, 2019 and 2018, respectively, and 55% and 56% of consolidated revenue for the nine months ended September 30, 2019 and 2018, respectively.

Debt

Debt	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Debt	5. Debt In September 2016, the Company entered into a loan and security agreement which includes a term loan and revolving line of credit facility, and initially borrowed $10.6 million as a term loan, known as Tranche A. In February 2018, the loan and security agreement was amended and restated. Under the terms of the amended and restated loan and security agreement, amounts available under Tranche A were increased to $30.0 million (the “Amended Tranche A”). As of the date of modification, the balance outstanding under Tranche A was $10.5 million. After giving consideration to the end of term payment, the Company borrowed an additional $19.5 million under the Amended Tranche A. Under the amended agreement, the Company had the option to borrow an additional $20.0 million as a term loan, known as the Amended Tranche B, beginning October 1, 2018 through June 30, 2019, or the date of an event of default if earlier, and the revolving line of credit facility was increased from $5.0 million to up to $25.0 million. Monthly payments of interest were due under the Amended Tranche A term loan through June 30, 2019, with monthly installments of principal and interest due for 42 months thereafter. If the Amended Tranche B was borrowed, monthly installments of principal and interest were to be reduced to 36 months. In June 2019, the Company’s loan and security agreement was amended to extend the Company’s option to borrow the Amended Tranche B through December 31, 2019. Additionally, the interest-only period was extended to December 31, 2019, with monthly installments of principal and interest due for 36 months thereafter. The term loan accrues interest at the greater of the floating per annum rate equal to the greater of The Wall Street Journal prime rate plus 2.0% or 6.25%. Additionally, an end of term payment is due to the lender in the amount of $1.8 million upon maturity, prepayment or acceleration of the term loan, as amended. The end of term payment is being accreted as additional interest expense over the term of the debt using the effective interest method. In connection with the amendment, the Company paid a one-time The term loan can be repaid prior to the maturity date, however, a prepayment fee of 3.0% of the outstanding principal balance will be due in addition to all outstanding principal and interest, if the prepayment is made before the first anniversary date of the loan closing date. This prepayment fee decreases to 2.0% if the prepayment is made on or after the first anniversary of the loan closing date but before the second anniversary of the loan closing date and the fee decreases to 1.0% of the outstanding principal amount if paid after the second anniversary and prior to the maturity date. The loan and security agreement provides the Company with a revolving line of credit of up to $25.0 million through December 2022. The amount available on the revolving line of credit is based on 80% of eligible receivables and is subject to a borrowing base calculation. Principal amounts outstanding under the revolving line of credit accrue interest at the greater of a floating per annum rate equal to the greater of The Wall Street Journal prime rate plus 0.25% or 4.5% and are repayable monthly. Upon termination of the agreement for any reason prior to the revolving credit facility’s maturity date, a termination fee of $250,000 will be due in addition to all outstanding principal and interest. Additionally, the revolving line of credit has a nonrefundable annual commitment fee of $62,500 payable on each anniversary date. In August 2019, the Company borrowed $11.0 million under the revolving line of credit. As of September 30, 2019, the entire $11.0 million was repaid. In connection with the amendment of the loan and security agreement, the Company issued the lender a warrant to purchase 125,000 Class A common shares with an exercise price per share of $1.62. The warrants had an estimated fair value of $150,000 which has been recorded as a debt discount. The Company had previously issued warrants to purchase an aggregate of 141,099 additional Class A common shares in connection with the loan. Thus, following the amendment of the loan and security agreement, the Company had issued warrants to purchase an aggregate of 266,099 Class A common shares. In September 2019, all then-outstanding warrants were net exercised which resulted in the issuance of an aggregate of 261,024 shares of common stock. If the Company borrows under the Amended Tranche B term loan, the Company is obligated to issue the lender a warrant to purchase an additional 133,000 Class A common shares with an exercise price per share of $1.62. Amounts borrowed under the loan and security agreement are collateralized by all of the Company’s assets, except for intellectual property, but including the proceeds from the sale of any of the Company’s intellectual property. In addition, the Company has provided a negative pledge regarding its intellectual property and cannot encumber it without the lender’s consent. The loan and security agreement contains various covenants for reporting, protecting and obtaining adequate insurance coverage for assets collateralized and for coverage of business operations, and complying with requirements, including the payment of all necessary taxes and fees for all federal, state and local government entities. Immediately upon the occurrence and during the continuance of an event of default, including the noncompliance with the above covenants, the lender may increase the interest rate per annum by 5.0% above the rate that is otherwise applicable; stop future loan advances; require the Company to deposit 105% of any undrawn letters of credit, or 110% if the letter of credit is denominated in a foreign currency; and take control over all assets collateralizing the loan and take necessary means to protect the collateral. The loan and security agreement contains a material adverse change clause, including terms for subjective acceleration. As of September 30, 2019 and as of the date these financial statements were available to be issued, the Company was in compliance with all loan covenants.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies Litigation The Company is currently a defendant in the lawsuits and proceedings described below. Other than with respect to the 2015 Delaware Action, losses are not probable or estimable for the described below. The 2015 Delaware Action In February 2015, Raindance Technologies, Inc. (“Raindance”) and the University of Chicago filed suit against the Company in the U.S. District Court for the District of Delaware, alleging that substantially all of the Company’s products that use the Company’s GEM microfluidic chips infringe certain patents. In May 2017, Bio-Rad (“Bio-Rad”) Bio-Rad Bio-Rad pre- In response to the jury award, the Company established an accrual of $30.6 million as of December 31, 2018, which was recorded as an operating expense on the consolidated statement of operations for the year ended December 31, 2018. Additionally, beginning in the fourth quarter of 2018, the Company also began recording an accrual for estimated royalties to Bio-Rad In July 2019, the Court awarded supplemental damages for the period from June 30, 2018 through the end of the trial in November 2018 and established the interest rates for pre- Bio-Rad pre-and Bio-Rad’s In July 2019, the Court also granted Bio-Rad Bio-Rad In August 2019, the Court ordered that the Company may post a bond in the amount of $52 million in lieu of payment of the final judgment. On September 13, 2019, the Company posted a $52 million bond (the “Bond”) in lieu of payment of the judgment pending the Company’s ongoing appeal. In connection with the Bond, the Company deposited $45 million as collateral in a segregated cash account, where it will be held until the conclusion of the appeal. The ITC 1068 Action On July 31, 2017, Bio-Rad 60-day The Northern District of California Action On July 31, 2017, Bio-Rad The Germany Action On July 31, 2017, Bio-Rad Bio-Rad On February 13, 2018, Bio-Rad Bio-Rad The 2018 Delaware Action On October 25, 2018, Bio-Rad On October 25, 2019, the Company filed inter partes Bio-Rad The 2019 Delaware Action On September 11, 2019, Bio-Rad 5 Bio-Rad The Becton, Dickinson Action On November 15, 2018, Becton, Dickinson and Company (“BD”) and Cellular Research, Inc. filed suit against the Company in the U.S. District Court for the District of Delaware, alleging that the Company infringed certain patents. In September 2019, the Company filed counterclaims alleging that BD and Cellular Research, Inc. (together, the “BD Entities”) infringed a number of the Company’s patents. This case was dismissed with prejudice on October 21, 2019 following the entrance by the parties into a settlement and patent cross license agreement. The Company considers this matter closed. See Note 10.

Equity Incentive Plans

Equity Incentive Plans	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Equity Incentive Plans	7. Equity Incentive Plans 2012 Stock Plan In October 2012, the Company adopted the 10x Genomics, Inc. 2012 Stock Plan (the “2012 Stock Plan”) which has been amended in subsequent years for increases in authorized shares, among other changes. The 2012 Stock Plan allowed for the issuance of incentive stock options (“ISOs”), non-statutory Upon the adoption of the 2019 Omnibus Incentive Plan in September 2019, any awards outstanding under the 2012 Stock Plan will continue to be governed by their existing terms but no further awards may be granted under the 2012 Stock Plan. 2019 Omnibus Incentive Plan In July 2019, in connection with the IPO, the Company’s board of directors adopted the 10x Genomics, Inc. 2019 Omnibus Incentive Plan (the “Omnibus Incentive Plan”), which was subsequently approved by the Company’s stockholders. The Omnibus Incentive Plan went into effect on September 11, 2019. The Omnibus Incentive Plan allows for the issuance of ISOs, NSOs or restricted shares. ISOs may be granted only to the Company’s employees (including officers and directors who are also considered employees). NSOs and restricted shares may be granted to the Company’s employees and service providers. As of September 30, 2019, the number of shares of Class A common stock issuable upon the exercise of stock options granted under the Omnibus Incentive Plan is 339,240. The Omnibus Incentive Plan provides that the total number of shares of the Company’s Class A common stock that may be issued under the Omnibus Incentive Plan is 11,000,000 (such share limit as increased from time to time, the “Absolute Share Limit”). However, the Absolute Share Limit shall be increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 5% of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year, the Company’s board of directors has not either confirmed the 5% increase described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, then the Company’s board of directors will be deemed to have waived the automatic increase, and no such increase will occur for such calendar year. Of the Absolute Share Limit, no more than 11,000,000 shares of Class A common stock may be issued in the aggregate pursuant to the exercise of incentive stock options granted under the Omnibus Incentive Plan. Options under the Omnibus Incentive Plan have a contractual term of 10 years. The exercise price of an ISO and NSO shall not be less than 100% of the fair market value of the shares on the date of grant. 2019 Employee Stock Purchase Plan In July 2019, the Company’s board of directors adopted the 10x Genomics, Inc. 2019 Employee Stock Purchase Plan (the “ESPP”), which was subsequently approved by the Company’s stockholders. The ESPP went into effect on September 11, 2019. Subject to any limitations contained therein, the ESPP allows eligible employees to contribute, through payroll deductions, up to 15% of their eligible compensation to purchase the Company’s Class A common stock at a discounted price per share. The ESPP generally provides for consecutive, overlapping 6-month A total of 2,000,000 shares of Class A common stock were reserved for issuance under the ESPP. As of September 30, 2019, no shares of Class A common stock have been purchased under the ESPP. The ESPP provides that the maximum number of shares of the Company’s Class A common stock made available for sale thereunder will be 2,000,000, which number will be automatically increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 1% of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year the Company’s board of directors has not either confirmed the 1% described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, the Company’s board of directors will be deemed to have waived the automatic increase and no such increase will occur for such calendar year. The maximum number of shares available under the ESPP (and any share limitations thereunder, as applicable) will automatically be adjusted upon certain changes to the Company’s capital structure. Stock-based Compensation The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands): Three months ended Nine months ended September 30, 2019 2018 2019 2018 Cost of revenue $ 81 $ 27 $ 171 $ 63 Research and development 1,650 230 3,448 670 Selling, general and administrative 2,143 332 4,639 862 Total stock-based compensation expense $ 3,874 $ 589 $ 8,258 $ 1,595

Income Tax

Income Tax	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Tax	8. Income Tax The Company’s provision for income taxes was $8,000 and $110,000 for the three and nine months ended September 30, 2019, respectively, with an effective tax rate of 0.1% and 0.5%, respectively, and $16,000 and $45,000 for the three and nine months ended September 30, 2018, respectively, with an effective tax rate of 0.1% and 0.1%, respectively. Deferred tax assets generated from the Company’s domestic net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized.

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Net Loss Per Share	9. Net Loss Per Share The following table sets forth the computation of basic and diluted net loss per share for the periods indicated (in thousands, except share and per share data): Three months ended September 30, Nine months ended 2019 2018 2019 2018 Net loss attributable to common stockholders $ (9,603 ) $ (15,345 ) $ (24,117 ) $ (36,961 ) Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted 29,184,218 13,587,288 19,904,184 13,188,322 Net loss per share attributable to common stockholders, basic and diluted $ (0.33 ) $ (1.13 ) $ (1.21 ) $ (2.80 ) The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: September 30, 2019 2018 Convertible preferred stock (on an if-converted — 64,954,871 Stock-options to purchase common stock 15,952,177 12,226,166 Shares subject to repurchase 164,375 163,750 Common stock warrants — 266,099 Shares committed under ESPP 2,438 — Total 16,118,990 77,610,886

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events The 2015 Delaware Action On October 10, 2019, the Court denied the Company’s motion to decrease the bond amount and stayed any execution or enforcement of the judgment until the completion of appeal, and for thirty days thereafter. The 2019 Becton, Dickinson Settlement and Patent Cross License Agreement In October 2019, the Company entered into a settlement and patent cross license agreement (the “BD Agreement”) with the BD Entities. The BD Agreement resolved all outstanding patent litigation between the parties (the “BD Litigation”), which was dismissed with prejudice on October 21, 2019. Under the terms of the BD Agreement, the BD Entities granted the Company and its affiliates, and the Company granted BD and its affiliates, a worldwide, royalty-free, non-exclusive, fully paid-up license Under the terms of the BD Agreement , the is obligated payments totaling comprised of four payments

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expense. These judgments, estimates and assumptions are used for, but not limited to, revenue recognition, inventory valuation and write-downs, loss contingencies, accounting for assets acquisitions and the fair value of common stock and stock option awards. The Company bases its estimates on various factors and information, which may include, but are not limited to, history and prior experience, the Company’s forecasts and future plans, current economic conditions and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. Actual results may differ from those estimates, and the differences may be material.
Segment Information	Segment Information The Company operates as a single operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance.
Cash Equivalents and Restricted Cash	Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and are stated at fair value. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows (in thousands): September 30, December 31, Cash and cash equivalents $ 427,436 $ 65,080 Restricted cash 50,053 5,008 Total cash, cash equivalents and restricted cash $ 477,489 $ 70,088
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company determines the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows: Level 1: Quoted prices in active markets for identical instruments Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Money market funds are highly liquid investments and are actively traded. The pricing information for the Company’s money market funds are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy. There were no transfers between Levels 1, 2 or 3 for any of the periods presented. As of September 30, 2019 and December 31, 2018, the Company held $406.9 million and $44.5 million in money market funds, respectively, with no unrealized gains or losses. The Company has issued common stock warrants for which fair value is determined using Level 3 inputs. See Note 5 for more on the common stock warrants.
Accounts Receivable, Net	Accounts Receivable, Net Accounts receivable consist of amounts due from customers for the sales of products and services. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability is no longer reasonably assured based on historical experience and specific customer collection issues. The allowance for doubtful accounts was $0.1 million and $0.3 million as of September 30, 2019 and December 31, 2018, respectively.
Business Concentrations	Business Concentrations The Company’s instruments are mostly assembled and tested by a single contract manufacturer in the United States. The Company’s agreement with the contract manufacturer expires in 2020 and may be terminated by either party for any reason by providing the other party with at least 30 days written notice. The Company’s agreement with the contract manufacturer contains purchase commitments. In addition, the Company is reliant on several suppliers for key components for its reagent kits. A significant disruption in the operations of the contract manufacturer or suppliers may impact the production of the Company’s products for a substantial period of time, which could have a material adverse effect on its business, financial condition and results of operations.
Concentrations	Concentrations Financial instruments that potentially subject the Company to credit risk consist of cash equivalents and accounts receivable. The Company’s cash and cash equivalents are primarily held with a large financial institution in the United States and deposits exceed the Federal Deposit Insurance Corporation’s insurance limit. The Company’s debt is with this same financial institution. The Company performs periodic evaluations of the risks associated with its investments and the relative credit standing of this financial institution. The Company performs ongoing credit evaluations of its customers’ financial condition. The Company does not require collateral from its customers but may require upfront payments from certain customers. The Company has not experienced significant credit losses to date. For the three and nine months ended September 30, 2018 and 2019, no single customer represented more than 10% of revenue. As of September 30, 2019 and December 31, 2018, no single customer represented more than 10% of the Company’s outstanding accounts receivable. Substantially all the Company’s long-lived assets are located in the United States.
Inventory	Inventory Inventory is recorded at the lower of cost, determined on a first-in, first-out basis,
Property and Equipment, Net	Property and Equipment, Net Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of the assets. Assets held under capital leases are recorded at the lower of the net present value of the minimum lease payments or the fair value of the leased assets at the inception of the lease. Amortization expense is computed using the straight-line method over the shorter of the estimated useful lives of the leased assets or the period of the related lease. Amortization of assets under capital leases is included in depreciation expense.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates long-lived assets, such as property and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist and the undiscounted future cash flows that the assets are expected to generate are less than the carrying value of the assets, the Company reduces the carrying amount of the assets to their estimated fair values based on a discounted cash flow approach or, when available and appropriate, to comparable market values. There were no impairment losses recorded for the three and nine month periods ended September 30, 2019 and 2018.
Product Warranties	Product Warranties The Company generally provides a one-year warranty
Deferred Revenue	Deferred Revenue Deferred revenue consists of payments received in advance of revenue recognition primarily related to instrument service agreements, also referred to as extended warranties. Revenue under these agreements is recognized over the related service period. Deferred revenue that will be recognized during the 12 months following the balance sheet date is recorded as current portion of deferred revenue and the remaining portion is recorded as long term.
Accrued Contingent Liabilities	Accrued Contingent Liabilities Accrued contingent liabilities represents the Company’s estimates of possible losses on pending litigations, including related accrued royalties that are both probable and reasonably estimable. See Note 6.
Revenue Recognition	Revenue Recognition Commencing on January 1, 2019, the Company recognized revenues in accordance with Accounting Standards Codification ( “ ASC ” ) Topic 606 – Revenue from Contracts with Customers. The Company generates revenue from sales of products and services. The Company’s products consist of instruments and consumables. The Company also sells instrument service agreements which relate to extended warranties. The Company recognizes revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. In instances where right of payment or transfer of title is contingent upon the customer’s acceptance of the product, revenue is deferred until all acceptance criteria have been met. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year one-year The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts.
Contract Costs	Contract Costs Sales commissions earned by the Company’s sales force are considered incremental and recoverable costs of obtaining a contract with a customer. Sale commissions related to the sale of extended warranties are deferred and amortized on a straight-line basis over the service term, which is typically greater than 1 year from the contract date. Amortization of deferred commissions is included in sales and marketing expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.
Cost of Revenue	Cost of Revenue Costs of revenue primarily consist of manufacturing costs incurred in the production process, including personnel and related costs, component materials, labor and overhead, packaging and delivery costs and allocated costs including facilities and information technology. In addition, costs of product revenue includes royalty costs for licensed technologies included in the Company’s products, warranty costs and provisions for slow-moving and obsolete inventory. In addition, cost of revenue includes estimated accrued royalties related to the Bio-Rad
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling charged to customers are recorded as revenue. Shipping and handling costs are included in the Company’s cost of revenue.
Research and Development	Research and Development Research and development costs are expensed in the period incurred. Research and development expense consists of personnel and related costs, independent contractor costs, laboratory supplies, equipment maintenance, prototype and materials expenses, amortization of developed technology and intangibles and allocated costs including facilities and information technology. See Note 3 for discussion of in-process research
Stock-Based Compensation	Stock-Based Compensation The Company estimates the fair value of share-based payment awards granted to employees and directors on the grant date using the Black-Scholes option-pricing model. The fair value of share-based payment awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. Share-based payment awards that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based awards. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and the expected stock price volatility over the expected term. For all stock options granted, the Company calculated the expected term using the simplified method for “plain vanilla” stock option awards. The Company has limited publicly available stock information and therefore, the Company has used the historical volatility of the stock price of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues Stock-based compensation expense for nonemployee stock options is measured based on fair market value using the Black-Scholes option pricing model and is recorded as the options vest. Prior to January 1, 2019, nonemployee stock options subject to vesting were revalued periodically over the requisite service period, which was generally the same as the vesting term of the award. From January 1, 2019, the grant date fair market value of nonemployee stock options is recognized in the consolidated statements of operations on a straight-line basis over the requisite service period and forfeitures are recognized as they occur.
Foreign Currency	Foreign Currency For foreign subsidiaries where the functional currency is the local currency, assets and liabilities are translated to the U.S. dollar using month-end exchange For foreign subsidiaries where the functional currency is the U.S. dollar, monetary assets and liabilities are remeasured using exchange rates in effect at the balance sheet dates and non-monetary assets
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes, in which deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be reversed. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that includes the enactment date. A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company’s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not (greater than 50% likely) to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision. The Company calculates the current and deferred income tax provision based on estimates and assumptions that could differ from the actual results reflected in income tax returns filed in subsequent years. Adjustments based on filed income tax returns are recorded when identified. The amount of income tax paid is subject to examination by U.S. federal and state tax authorities. The estimate of the potential outcome of any uncertain tax issue is subject to management’s assessment of the relevant risks, facts and circumstances existing at that time. To the extent the assessment of such tax position changes, the change in estimate is recorded in the period in which the determination is made.
Net Loss Per Share	Net Loss Per Share Net loss per share of common stock is computed using the two-class method The Company’s participating securities included the Company’s convertible preferred stock, as the holders are entitled to receive noncumulative dividends on a pari passu basis in the event that a dividend is paid on common stock. The Company also considers any shares issued on the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. For the calculation of diluted net loss per share, basic net loss per share attributable to common stockholders is adjusted by the effect of dilutive securities, including convertible preferred stock, awards under the Company’s equity compensation plan and common stock warrants. Diluted net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.
Acquisitions of Assets	Acquisitions of Assets The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the requirements of a business. The Company accounts for an asset acquisition under Accounting Standards Codification (“ASC”), Business Combinations Topic 805, Subtopic 50 the non-monetary identifiable In-process Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting Compensation—Stock Compensation
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) right-of-use In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other – Internal Use Software (Subtopic 350-40) internal-use 350-40,

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Cash equivalents and restricted cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows (in thousands): September 30, December 31, Cash and cash equivalents $ 427,436 $ 65,080 Restricted cash 50,053 5,008 Total cash, cash equivalents and restricted cash $ 477,489 $ 70,088

Other Financial Statement Inf_2

Other Financial Statement Information (Tables)	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of inventory	Inventory was comprised of the following as of the dates indicated (in thousands): September 30, December 31, Purchased materials $ 4,365 $ 3,052 Work in progress 4,525 2,553 Finished goods 4,415 2,965 Inventory $ 13,305 $ 8,570
Schedule of accrued compensation and related benefits	Accrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands): September 30, December 31, Accrued bonus $ 4,517 $ 3,545 Accrued commissions 1,757 2,299 Other 1,576 1,203 Accrued compensation and related benefits $ 7,850 $ 7,047
Schedule of accrued expense And other current liabilities	Accrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands): September 30, December 31, Accrued royalties for licensed technologies $ 1,814 $ 1,571 Accrued property and equipment 5,367 990 Accrued consulting 763 741 Product warranties 409 804 Customer deposits 792 381 Taxes payable 740 738 Other 4,382 2,947 Accrued expenses and other current liabilities $ 14,267 $ 8,172
Schedule Of changes in the reserve for product warranties	Changes in the reserve for product warranties were as follows for the periods indicated (in thousands): September 30, December 31, Beginning of period $ 804 $ 174 Additions charged to cost of revenue 408 1,685 Repairs and replacements (803 ) (1,055 ) End of period $ 409 $ 804
Schedule of revenue by source	The following table represents revenue by source for the periods indicated (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Instruments $ 10,377 $ 9,193 $ 25,527 $ 25,057 Consumables 49,745 26,810 142,134 69,292 Services 1,085 604 2,943 1,410 Total revenue $ 61,207 $ 36,607 $ 170,604 $ 95,759
Schedule of revenue by geography	The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 North America $ 35,838 $ 21,391 $ 97,293 $ 56,932 Europe, Middle East and Africa 12,136 8,228 36,634 21,953 China 7,046 4,248 22,453 9,710 Asia Pacific 6,187 2,740 14,224 7,164 Total revenue $ 61,207 $ 36,607 $ 170,604 $ 95,759

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement, Disclosure [Abstract]
Recorded stock-based compensation expense in the condensed consolidated statement of operations	The Company recorded stock-based compensation expense in the condensed consolidated statement of operations for the periods presented as follows (in thousands): Three months ended Nine months ended September 30, 2019 2018 2019 2018 Cost of revenue $ 81 $ 27 $ 171 $ 63 Research and development 1,650 230 3,448 670 Selling, general and administrative 2,143 332 4,639 862 Total stock-based compensation expense $ 3,874 $ 589 $ 8,258 $ 1,595

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Computation of basic and diluted net loss per share	The following table sets forth the computation of basic and diluted net loss per share for the periods indicated (in thousands, except share and per share data): Three months ended September 30, Nine months ended 2019 2018 2019 2018 Net loss attributable to common stockholders $ (9,603 ) $ (15,345 ) $ (24,117 ) $ (36,961 ) Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted 29,184,218 13,587,288 19,904,184 13,188,322 Net loss per share attributable to common stockholders, basic and diluted $ (0.33 ) $ (1.13 ) $ (1.21 ) $ (2.80 )
Shares of common stock equivalents were excluded from the computation of diluted net loss per share	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: September 30, 2019 2018 Convertible preferred stock (on an if-converted — 64,954,871 Stock-options to purchase common stock 15,952,177 12,226,166 Shares subject to repurchase 164,375 163,750 Common stock warrants — 266,099 Shares committed under ESPP 2,438 — Total 16,118,990 77,610,886

Description of Business and B_2

Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Sep. 16, 2019	Sep. 15, 2019	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Entity incorporation, date of incorporation				Jul. 2, 2012
Common stock shares authorised			1,100,000,000	1,100,000,000		190,955,000
Preferred stock shares authorised		100,000,000	100,000,000	100,000,000		0
Common stock shares issued			96,118,804	96,118,804		14,549,801
Common stock shares outstanding			96,118,804	96,118,804		14,549,801
Cash flow from operations				$ 27,927	$ (25,410)
Cash and cash equivalents			$ 427,436	427,436		$ 65,080
Accumulated deficit			$ (255,233)	$ (255,233)		$ (231,116)
Common class A [Member]
Proceeds from Initial public offer	$ 410,800
Common stock shares converted		8,095,382	484,484
Common stock shares authorised		1,000,000,000
Common stock shares issued			20,849,374	20,849,374
Common stock shares outstanding			20,849,374	20,849,374
Common stock voting rights description				Each share of Class A common stock is entitled to one vote per share.
Common stock conversion, description				convertible at any time into one share of Class A common stock
Common class A [Member] | IPO [Member]
Common stock new issue shares	11,500,000
IPO offer price per share	$ 39
Offering costs, underwriting commissions and discounts	$ 37,700
Common class A [Member] | IPO [Member] | Underwriter offer [Member]
Common stock new issue shares	1,500,000
Common class B [Member]
Convertible preferred stock shares issued upon conversion		67,704,278
Common stock shares converted		8,050,000
Common stock shares authorised		100,000,000
Common stock shares issued			75,269,430	75,269,430
Common stock shares outstanding			75,269,430	75,269,430
Common stock voting rights description				Each share of Class B common stock is entitled to ten votes per share

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019USD ($)Segment	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)Segment	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)
Number of operating segment | Segment	1		1
Allowance or doubtful doubts	$ 100,000		$ 100,000		$ 300,000
Impairment of long lived assets	0	$ 0	$ 0	$ 0
Product warranty			The Company generally provides a one-year warranty on its instruments.
Foreign currency transaction losses	$ (100,000)	$ (100,000)	$ (200,000)	$ (200,000)
Maximum [Member]
Percentage of tax benefit recognised			50.00%
Revenue [Member]
Concentration risk percentage	10.00%	10.00%	10.00%	10.00%
Accounts receivable [Member]
Concentration risk percentage			10.00%		10.00%
Fair value, inputs, level 1 [Member] | Money market funds [Member]
Fair value of money market instruments	$ 406,900,000		$ 406,900,000		$ 44,500,000
Unrealised gains losses on money market instruments			$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Cash Equivalents and Restricted Cash (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	$ 427,436	$ 65,080
Restricted cash	50,053	5,008
Total cash, cash equivalents and restricted cash	$ 477,489	$ 70,088	$ 88,065	$ 47,857

Acquisition - Additional Infor

Acquisition - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Mar. 31, 2018	Sep. 30, 2018	Sep. 30, 2018
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
In-process research and development		$ 16,104	$ 22,310
Epinomics Inc [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
Business acquisition, Consideration net			22,200
Business acquisition costs		300	300
In-process research and development		16,000	$ 22,200
Epinomics Inc [Member] | Due upon closing of acquisition [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
Business acquisition, Consideration net	$ 6,200
Epinomics Inc [Member] | Due upon amendment and assignment of license agreement [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
Business acquisition, Consideration net		$ 16,000

Other Financial Statement Inf_3

Other Financial Statement Information - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Transaction price allocated to remaining performance obligations	$ 4,300		$ 4,300
Remaining performance obligations percentage	72.00%		72.00%
Contract liability	$ 4,300		$ 4,300
Contract Liability, short-term portion	3,082		3,082		$ 2,395
Revenues	$ 61,207	$ 36,607	$ 170,604	$ 95,759
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction: 2020-09-30
Expected period of revenue recognition	12 months		12 months
Revenue [Member]
Revenues	$ 600		$ 1,900
Percentage Of Revenue	10.00%	10.00%	10.00%	10.00%
US (included in North America) | Geographic Concentration Risk [Member] | Revenue [Member]
Percentage Of Revenue	57.00%	56.00%	55.00%	56.00%

Other Financial Statement Inf_4

Other Financial Statement Information - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Purchased materials	$ 4,365	$ 3,052
Work in progress	4,525	2,553
Finished goods	4,415	2,965
Inventory	$ 13,305	$ 8,570

Other Financial Statement Inf_5

Other Financial Statement Information - Schedule of Accrued Compensation and Related Benefits (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accrued bonus	$ 4,517	$ 3,545
Accrued commissions	1,757	2,299
Other	1,576	1,203
Accrued compensation and related benefits	$ 7,850	$ 7,047

Other Financial Statement Inf_6

Other Financial Statement Information - Schedule of Accrued Expense And Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accrued royalties for licensed technologies	$ 1,814	$ 1,571
Accrued property and equipment	5,367	990
Accrued consulting	763	741
Product warranties	409	804
Customer deposits	792	381
Taxes payable	740	738
Other	4,382	2,947
Accrued expenses and other current liabilities	$ 14,267	$ 8,172

Other Financial Statement Inf_7

Other Financial Statement Information - Schedule of Changes in the Reserve for Product Warranties (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Beginning of period	$ 804	$ 174
Additions charged to cost of revenue	408	1,685
Repairs and replacements	(803)	(1,055)
End of period	$ 409	$ 804

Other Financial Statement Inf_8

Other Financial Statement Information - Schedule of Revenue by Source (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues	$ 61,207	$ 36,607	$ 170,604	$ 95,759
Instuments [Member]
Revenues	10,377	9,193	25,527	25,057
Consumables [Member]
Revenues	49,745	26,810	142,134	69,292
Service [Member]
Revenues	$ 1,085	$ 604	$ 2,943	$ 1,410

Other Financial Statement Inf_9

Other Financial Statement Information - Schedule of Revenue by geography (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues	$ 61,207	$ 36,607	$ 170,604	$ 95,759
North America [Member]
Revenues	35,838	21,391	97,293	56,932
Europe, Middle East and Africa [Member]
Revenues	12,136	8,228	36,634	21,953
China [Member]
Revenues	7,046	4,248	22,453	9,710
Asia Pacific [Member]
Revenues	$ 6,187	$ 2,740	$ 14,224	$ 7,164

Debt - Additional information (

Debt - Additional information (Detail) - USD ($)	1 Months Ended		9 Months Ended
	Feb. 28, 2018	Sep. 30, 2016	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2019	Oct. 01, 2018
Debt Instrument [Line Items]
Term loan borrowed				$ 19,512,000
Revolving line of credit borrowed			$ 11,000,000
Revolving line of credit repaid			$ 11,000,000
Estimated fair value of the warrants	$ 150,000
Common stock shares issued as a result of warrant exercises			261,024
Penal interest rate spread			5.00%
Debt Instrument, Debt Default, Description of Violation or Event of Default			Immediately upon the occurrence and during the continuance of an event of default, including the noncompliance with the above covenants, the lender may increase the interest rate per annum by 5.0% above the rate that is otherwise applicable; stop future loan advances; require the Company to deposit 105% of any undrawn letters of credit, or 110% if the letter of credit is denominated in a foreign currency; and take control over all assets collateralizing the loan and take necessary means to protect the collateral.
Common class A [Member]
Debt Instrument [Line Items]
Number Of Securities Called By Warrants	266,099	141,099
Letter of Credit [Member]
Debt Instrument [Line Items]
Deposit percentage			105.00%
Foreign Letter Of Credit [Member]
Debt Instrument [Line Items]
Deposit percentage			110.00%
Revolving Credit Facility
Debt Instrument [Line Items]
Debt Instrument, maximum borrowing capacity			$ 25,000,000		$ 25,000,000	$ 5,000,000
Debt Instrument, Expiration Date			Dec. 30, 2022
Line of credit facility available as a percentage of receivables			80.00%
Line of credit facility interest rate description			Principal amounts outstanding under the revolving line of credit accrue interest at the greater of a floating per annum rate equal to the greater of The Wall Street Journal prime rate plus 0.25% or 4.5% and are repayable monthly.
Non refundable annual commitment fee			$ 62,500
Revolving line of credit borrowed			11,000,000
Revolving line of credit repaid			11,000,000
Line of credit facility, termination fee			$ 250,000
Revolving Credit Facility | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument spread on variable rate			0.25%
Revolving Credit Facility | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument spread on variable rate			4.50%
Tranche A | Term Loan [Member]
Debt Instrument [Line Items]
Term loan borrowed		$ 10,600,000
Amended Tranche A | Term Loan [Member]
Debt Instrument [Line Items]
Term loan outstanding	$ 10,500,000
Amended Tranche A | Term Loan [Member] | Common class A [Member]
Debt Instrument [Line Items]
Number Of Securities Called By Warrants	125,000
Exercise price per share	$ 1.62
Amended Tranche B | Term Loan [Member] | Common class A [Member]
Debt Instrument [Line Items]
Number Of Securities Called By Warrants			133,000
Exercise price per share			$ 1.62
Long-Term Debt | Term Loan [Member]
Debt Instrument [Line Items]
Term loan description of variable interest rate			The term loan accrues interest at the greater of the floating per annum rate equal to the greater of The Wall Street Journal prime rate plus 2.0% or 6.25%
Interest expense due			$ 1,800,000
One time fees paid			$ 50,000
Long-Term Debt | Term Loan [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument spread on variable rate			2.00%
Long-Term Debt | Term Loan [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument spread on variable rate			6.25%
Long-Term Debt | Term Loan [Member] | Before the first anniversary of loan closing
Debt Instrument [Line Items]
Prepayment fees percentage			3.00%
Long-Term Debt | Term Loan [Member] | After the first anniversary of loan closing to before the second anniversary of loan closing
Debt Instrument [Line Items]
Prepayment fees percentage			2.00%
Long-Term Debt | Term Loan [Member] | After the second anniversary of loan closing to before maturity date
Debt Instrument [Line Items]
Prepayment fees percentage			1.00%
Long-Term Debt | Amended Tranche A | Term Loan And Revolving Line Of Credit Facility
Debt Instrument [Line Items]
Line of credit monthly instalments-principal and interest			36 months
Long-Term Debt | Amended Tranche A | Term Loan [Member]
Debt Instrument [Line Items]
Term loan borrowed	$ 19,500,000
Debt Instrument, maximum borrowing capacity	30,000,000
Term loan frequency of payment terms			Monthly payments of interest were due under the Amended Tranche A term loan through June 30, 2019
Debt Instrument, Amended Maturity Date			Dec. 31, 2019
Long-Term Debt | Amended Tranche B | Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument, additional borrowing capacity	$ 20,000,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended	12 Months Ended
	Nov. 30, 2018	Jun. 30, 2018	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2019	Dec. 31, 2018	Sep. 13, 2019
Accrual provision					$ 1,360
Bio RadLaboratories Inc [Member]
Damages awarded	$ 35,000	$ 24,000
Royalty percentage on sales				15.00%
Royalty expense				$ 7,400
Loss contingency			$ 62,500	$ 38,000	62,500	$ 38,000
Bond amount							$ 52,000
Bio RadLaboratories Inc [Member] | Assets Held In Trust [Member]
cash collateral							$ 45,000
Bio RadLaboratories Inc [Member] | Operating Expense [Member]
Accrual provision						$ 30,600
Pre and post judgment interest					1,400
Bio RadLaboratories Inc [Member] | Cost of Sales [Member]
Royalty expense			$ 7,200		$ 23,100

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2019shares
2019 Omnibus Incentive Plan [Member]
contractual term	10 years
2019 Omnibus Incentive Plan [Member] | Minimum [Member]
Exercise price percentage on fair market value	100.00%
2019 Employee Stock Purchase Plan [Member]
Offering period	6 months
Common stock purchased under plan	0
Percentage increase in shares on stock outstanding	1.00%
Employee contribution percentage	15.00%
Common Class A [Member] | 10x Genomics, Inc. 2012 Stock Plan [Member]
Common stock issuable upon the exercise of stock options	15,612,937
Common Class A [Member] | 2019 Omnibus Incentive Plan [Member]
Common stock issuable upon the exercise of stock options	339,240
Common stock available for sale	11,000,000
Common Class A [Member] | 2019 Employee Stock Purchase Plan [Member]
Common stock reserved for issuance	2,000,000

Equity Incentive Plans - Record

Equity Incentive Plans - Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 3,874	$ 589	$ 8,258	$ 1,595
Cost of revenue [Member]
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	81	27	171	63
Research and development [Member]
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	1,650	230	3,448	670
Selling, general and administrative [Member]
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 2,143	$ 332	$ 4,639	$ 862

Income Tax - Additional Informa

Income Tax - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 8	$ 16	$ 110	$ 45
Effective tax rate	0.10%	0.10%	0.50%	0.10%

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Earnings Per Share [Abstract]
Net loss attributable to common stockholders	$ (9,603)	$ (10,878)	$ (3,636)	$ (15,345)	$ (5,923)	$ (15,693)	$ (24,117)	$ (36,961)
Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted	29,184,218			13,587,288			19,904,184	13,188,322
Net loss per share attributable to common stockholders, basic and diluted	$ (0.33)			$ (1.13)			$ (1.21)	$ (2.80)

Net Loss Per Share - Shares of

Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Detail) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	16,118,990	77,610,886
Convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		64,954,871
Stock-options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	15,952,177	12,226,166
Shares subject to repurchase [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	164,375	163,750
Common stock warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		266,099
Shares committed under ESPP [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,438

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Becton dickinson settlement and patent cross license agreement [Member] - Subsequent Event [Member] $ in Thousands	Oct. 21, 2019USD ($)Annual-Payments
Subsequent Event [Line Items]
License annual payment	$ 6,250
License number of annual payments | Annual-Payments	4
License value total	$ 25,000